Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05128825 · ClinicalTrials.gov registry record · Phase 2
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase 2 study of High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
- 20
- Study locations
NCT05128825 is a Phase 2 study of High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer that is actively recruiting participants, run by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals. The registered enrollment target is 170 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT05128825, a Phase 2 study of High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer, is actively recruiting participants, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conducted in subjects whose tumors are Cyclin E1 positive as determined by central review using the Sponsor's investigational clinical trial assay.
Conditions Studied
Interventions
- DRUG azenosertib
Study Locations (20)
Florida
- Site 0239 - Florida Cancer Specialists - East - Daytona Beach
- Site 0173 - Mount Sinai Medical Center - Miami Beach
- Site 0308 - Advent Health - Orlando
Massachusetts
- Site 0221 - Tufts Medical Center - PPDS - Boston
- Site 0104 - Dana Farber Cancer Institute - Boston
- Site 0307 - Lahey Hospital and Medical Center - Burlington
Arizona
- Site 0143 - HonorHealth - Phoenix
- Site 0102 - University of Arizona Cancer Center - Tucson
California
- Site 0258 - UC San Diego Moores Cancer Center - La Jolla
- Site 0287 - Ridley Tree Cancer Center - Santa Barbara
Georgia
- Site 0108 - Emory University Hospital - Atlanta
- Site 0236 - Memorial Health - Savannah
Indiana
- Site 0284 - Community Cancer Center North - Indianapolis
- Site 0217 - St Vincent Hospital and Health Care Centers - Indianapolis
Alabama
- Site 0170-USA Mitchell Cancer Institute - Mobile
Colorado
- Site 0135 - Rocky Mountain Cancer Centers - Lone Tree
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2022-02-17 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05128825
The ClinicalTrials.gov registry entry for NCT05128825 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer appearing as the primary indexed condition, and to 1 intervention - of which azenosertib is the first listed.
NCT05128825 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Massachusetts, Arizona.
Frequently Asked Questions
What is clinical trial NCT05128825 about?
NCT05128825 is a clinical study titled "A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer". This is a multi-part Phase 2 study to evaluate the efficacy and safety of azenosertib (ZN-c3) in subjects with Platinum-Resistant, High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Part 2 of the study will be conducted in subjects whose tumors are Cyclin E1 positive as determi...
What is the current status of trial NCT05128825?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2022-02-17. Estimated completion is 2027-06-30.
What conditions does trial NCT05128825 study?
This clinical trial studies the following conditions: High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
What interventions are being tested in trial NCT05128825?
The interventions under investigation include: azenosertib (DRUG).
Who is sponsoring clinical trial NCT05128825?
This trial is sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05128825 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.